Early termination of NCT04617067, a phase II, open label, clinical trial of oral paricalcitol in combination with gemcitabine and NAB-paclitaxel therapy in advanced pancreatic cancer
NCT04617067 是一项 II 期、开放标签的临床试验，旨在评估口服帕立骨化醇联合吉西他滨和 NAB-紫杉醇疗法治疗晚期胰腺癌的疗效，该试验已提前终止。
期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-025-14512-2
Easty, David; McDermott, Ray; Murphy, Adrian G; Grogan, Liam; Morris, Patrick G; Breathnach, Oscar S; Egan, Keith; Toomey, Sinead; Horgan, Anne; Power, Derek; Osman, Nemer; Parker, Imelda; Donachie, Vicky; Shevlin, Anna; Barrett, Aisling; Nolan, Marc; Marron, Jacinta; Farr, Christine J; Hennessy, Bryan T
